AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02810665 — intervention group
Intervention type: BEHAVIORAL
Intervention: Visual acuity measurement by ETDRS chart
Description: All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
Study NCT02829138 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic information and Omega-3 fat intake
Description: Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
Study NCT02829138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Nutrition related to Omega-3 fats
Description: Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
Study NCT02829138 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Nutrition related to Omega-3 fats
Description: Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
Study NCT04510233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin nasal
Description: Ivermectin nasal spray one ml in each nostril two times daily
Study NCT04510233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin oral
Description: Ivermectin oral (one tablet 6 mg three times daily)
Study NCT04510233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: oxygen via masks or ventilators
Study NCT00712699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: XR-MAS then placebo
Description: XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Study NCT00712699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 Placebo then XR-MAS
Description: PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Study NCT00577785 — intervention group
Intervention type: OTHER
Intervention: tissue procurement
Description: No intervention. Tissue procurement study.
Study NCT04243590 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hand-Use-at-Home Questionnaire (HUH)
Description: The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
Study NCT04243590 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pediatric Outcome Data Collection Instrument (PODCI)
Description: The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
Study NCT04243590 — intervention group
Intervention type: BEHAVIORAL
Intervention: Children's Hand-Use Experience Questionnaire (CHEQ)
Description: The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study.
Study NCT04819152 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tobacco cessation intervention
Description: Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
Study NCT03666455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
Study NCT02411539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Study NCT02411539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Study NCT04715061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting state (Control)
Description: Participants were asking to sit on a sofa for 50 minutes.
Study NCT04715061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting state (Control)
Description: Participants were asking to sit on a sofa for 50 minutes.
Study NCT04715061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Description: MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
Study NCT04715061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Description: HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels > 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
Study NCT04715061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Exercise (HIIE)
Description: HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels > 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
Study NCT01002235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Intramuscular injections in the calf on Day 0 and Day 14.
Study NCT03016325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion
Study NCT03016325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study NCT01956903 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogenic Mesenchymal Stem Cell
Description: Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)
Study NCT03961815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Induction Dose
Description: Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
Study NCT03961815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Maintenance Dose
Description: Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
Study NCT02231164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: intravenous chemotherapy drug
Study NCT02231164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: intravenous chemotherapy drug
Study NCT02231164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo
Study NCT02231164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: oral experimental therapy
Study NCT04241211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forsteo
Description: Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
Study NCT04241211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Prefilled Syringe [Prolia]
Description: Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
Study NCT01774578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Lung Immunotherapy
Description: HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Study NCT01774578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Study NCT04075838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recovery group
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study NCT00823498 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: 6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
Study NCT00823498 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview with a member of study staff at housing development site.
Study NCT00823498 — intervention group
Intervention type: OTHER
Intervention: Photovoice Project
Description: Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
Study NCT03009032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMT25341
Study NCT03009032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study NCT02012985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxabact OC5 capsules
Description: The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
Study NCT02012985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
Study NCT00606320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg(4 tablets)/day
Study NCT05815407 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02086786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM
Description: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.
Study NCT03317795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUS
Description: LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
Study NCT03317795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
Study NCT04383860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5-0 suture
Description: 5-0 suture administration during surgery
Study NCT04383860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-0 suture
Description: 4-0 suture administration during surgery
Study NCT03187431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mesenchymal stem cells
Description: intravenous infusion
Study NCT02189161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (Barrx™)
Description: Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
Study NCT03412175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
Study NCT01087905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: If > 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day
Study NCT01087905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
Study NCT01087905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMAC
Description: CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
Study NCT02897700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate
Description: Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
Study NCT02897700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)
Description: Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
Study NCT02897700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 200 mg
Description: IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 250 mg
Description: IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: Active comparator containing 25 mg carbidopa and 100 mg levodopa
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD CR
Description: Active comparator containing 50 mg carbidopa and 200 mg levodopa
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 200 mg Placebo
Description: Placebo to match IPX054 200 mg
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 250 mg Placebo
Description: Placebo to match IPX054 250 mg
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR Placebo
Description: Placebo to match CD-LD IR
Study NCT00279825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD CR Placebo
Description: Placebo to match CD-LD CR
Study NCT01347554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
Study NCT01347554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
Study NCT03058042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises of the pelvic floor muscle at home
Description: Patients will perform pelvic floor exercises at home.
Study NCT03058042 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercises of the pelvic floor muscle in the outpatient
Description: Patients will perform pelvic floor exercises in the outpatient.
Study NCT00812058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG2417
Description: 1g bid dose escalates to 2g bid for weeks 2-8.
Study NCT00812058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
Study NCT01880931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The effect site concentration of remifentanil